Wara Samar
27th March 2025
Supira Medical Closes $120M Series E Funding, Wraps Up SUPPORT I Early Feasibility Study Enrollment
Supira Medical, Inc. (Supira), a clinical-stage Shifamed portfolio company, has successfully secured $120 million in an oversubscribed Series E funding round. The financing, led by new investors Novo Holdings and Qatar Investment Authority (QIA), also included contributions from two undisclosed strategic investors and continued support from existing backers such as Cormorant Asset Management, The Capital Partnership (TCP), 415 Capital, AMED Ventures, PA MedTech VC Fund, and Unorthodox Ventures.
The newly raised capital will be directed toward advancing Supira’s clinical programs, specifically targeting high-risk percutaneous coronary intervention (HRPCI) and cardiogenic shock (CS). A significant portion of the funding will support the upcoming SUPPORT II U.S. Pivotal Study for HRPCI, an essential step in securing FDA premarket approval (PMA). The investment underscores growing confidence in Supira’s mission to enhance the percutaneous ventricular assist device (pVAD) market with its advanced low-profile, high-flow technology platform.
Completion of SUPPORT I Early Feasibility Study
In addition to securing substantial funding, Supira has successfully completed enrollment for its U.S. SUPPORT I Early Feasibility Study (EFS). This prospective, single-arm study enrolled 15 patients across four clinical sites to evaluate the safety and feasibility of Supira’s innovative pVAD in HRPCI procedures. The completion of this study represents a key milestone in the company’s efforts to bring next-generation cardiovascular support technologies to market.
pVADs play a critical role in providing temporary circulatory support during HRPCI, particularly for patients with complex coronary anatomy, compromised hemodynamics, and multiple comorbidities. They are also crucial in managing cardiogenic shock, a severe condition characterized by insufficient cardiac output, often resulting from heart failure or myocardial infarction. While the Supira System remains an investigational device and is not yet approved for sale, its clinical progress signals promise for improving patient outcomes in these high-risk settings.
Strategic Growth and Industry Support
Alongside the Series E funding, Supira has expanded its leadership team by welcoming Dr. Christopher Shen, Partner at Novo Holdings US, to its Board of Directors. His expertise will contribute valuable strategic insights as the company continues its clinical and regulatory journey.
Piper Sandler served as the exclusive financial advisor for the transaction, while Sidley Austin LLP provided legal counsel.
With a strong financial foundation and a clear roadmap for clinical validation, Supira Medical is positioned to advance its next-generation pVAD technology, addressing critical unmet needs in interventional cardiology. As the company advances its pivotal clinical studies, it continues to refine and enhance cardiovascular support solutions with its innovative approach.
Join Us at MedTech Malta 2025
MedTech Malta 2025 is set to take place from 12 to 14 November in Valletta, Malta, bringing together global innovators, investors, and healthcare pioneers. Whether you’re looking to showcase your technology, explore sponsorship opportunities, or engage in discussions advancing MedTech, this is the platform to make an impact.
Seize the opportunity to connect with key stakeholders, gain visibility in a rapidly evolving industry, and be at the forefront of conversations that matter. Don’t miss your chance to be part of Europe’s premier MedTech event—reach out today at [email protected] to discuss how you can get involved!
